Form & Formulation banner

Are you calling in the cavalry too late? Closing the stable door after the horse has already bolted? Or, in other words, initiating conversations with form & formulation experts too late in the drug discovery process? Don't sweat it. We've got the winning formula. 

Join us on the 9th of June, with a follow up date TBC, at 15:00 - 15:30pm (BST), for 2 x 30 minute, interactive sessions with drug formulation thought-leaders from within Sygnature Discovery. Learn how to de-risk your project, optimize the DMPK properties of your molecule, and get off the lab bench into the clinic quickly and safely. For further details, see the episode abstracts below. 

Sign up today!

Episode 1: Form & Formulation: Advancing projects to the clinic faster
9th June, 2022, 15:00 - 15:30pm (BST)
David Pearson, Director of Form & Formulation at Sygnature Discovery 
David Pearson

Learn how rapid and early access to solid form and formulation expertise early in a drug discovery and development project can help advance your molecules to the patients that need them. Whether you are looking to obtain optimal exposure in your pre-clinical models or understand, control or modify  the solid form properties of your drug substance feeding your drug product, access to technologies and expertise can de-risk and accelerate your project.

Episode 2: Combining DMPK with Form & Formulation thinking and delivery; a recipe for success
Date TBC, 2022, 15:00 - 15:30pm (BST)
Richard Weaver, Senior Vice President of Pre-clinical Development at Sygnature Discovery 
Richard RDD

Poor solubility continues to be a recognised challenge in small molecule R&D.  Although the poor solubility is often improved via an enabling formulation, maximum bioavailability may still be unacceptable. In fact, the main driver of this may be nothing to do with the solubility and rather the poor overall DMPK properties of the molecule. In this webinar, you will learn how DMPK understanding of the individual parameters that manifest in total bioavailability should be used in early to mid-discovery along with engagement and scientific influence by the form & formulation scientists. If done properly, the risk of unacceptable bioavailability will be fully mitigated against to allow progression from the regulatory toxicology studies to the clinic.